Saniona AB
STO:SANION
Saniona AB
Revenue
Saniona AB
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Saniona AB
STO:SANION
|
Revenue
kr26.7m
|
CAGR 3-Years
28%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Revenue
kr21.5B
|
CAGR 3-Years
37%
|
CAGR 5-Years
32%
|
CAGR 10-Years
38%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Revenue
kr62.7m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-9%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Revenue
€363.6m
|
CAGR 3-Years
260%
|
CAGR 5-Years
94%
|
CAGR 10-Years
39%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Revenue
kr6.1B
|
CAGR 3-Years
57%
|
CAGR 5-Years
61%
|
CAGR 10-Years
20%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Revenue
kr34.9m
|
CAGR 3-Years
12%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Saniona AB
Glance View
Saniona AB engages in the research and development on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases, and treatment of pain. The company operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The firm develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The firm is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.
See Also
What is Saniona AB's Revenue?
Revenue
26.7m
SEK
Based on the financial report for Sep 30, 2024, Saniona AB's Revenue amounts to 26.7m SEK.
What is Saniona AB's Revenue growth rate?
Revenue CAGR 5Y
40%
Over the last year, the Revenue growth was 80%. The average annual Revenue growth rates for Saniona AB have been 28% over the past three years , 40% over the past five years .
You don't have any saved screeners yet